Calliditas Therapeutics Ab ((CALT)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Calliditas Therapeutics AB has recently completed a Phase 2a clinical study titled A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome. The study aimed to assess the safety and tolerability of setanaxib, a NOX1/4 inhibitor, in patients with Alport syndrome, a genetic condition affecting kidney function. The significance of this study lies in its potential to enhance treatment options for Alport syndrome by preserving kidney function when setanaxib is added to the standard of care.
The intervention being tested is setanaxib, a first-in-class inhibitor of the human protein NADPH NOX1/4. It is designed to work alongside existing treatments to provide additional therapeutic benefits for patients with Alport syndrome.
The study was interventional, with a randomized, parallel assignment model. It employed a triple-masking approach, meaning that the participant, care provider, and investigator were unaware of the treatment assignments. The primary purpose of the study was treatment-focused, aiming to evaluate the efficacy and safety of setanaxib compared to a placebo.
The study commenced on November 27, 2023, and was completed with the last update submitted on July 22, 2025. These dates are crucial as they mark the timeline of the study’s progression and the availability of its findings.
The completion of this study could have significant market implications for Calliditas Therapeutics AB, potentially boosting investor confidence and stock performance due to the promising therapeutic benefits of setanaxib. In the broader industry context, this development might influence the competitive landscape for treatments targeting Alport syndrome.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.